Pacira | PCRX - Current Assets


Pacira reported $514.96M in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
Astellas Pharma JPY 1.42T 19.35B Mar/2026
Bristol-Myers Squibb USD 27.21B 2.18B Mar/2026
Cara Therapeutics USD 31.54M 6.9M Dec/2025
Coherus Biosciences USD 206.71M 254.25M Dec/2025
Heron Therapeutics USD 228.98M 9.08M Mar/2026
Ironwood Pharmaceuticals USD 332.29M 58.11M Mar/2026
J&J USD 59.17B 3.55B Mar/2026
Ligand Pharmaceuticals USD 865.42M 33.14M Mar/2026
Nektar Therapeutics USD 266.27M 15.09M Dec/2025
Novo Nordisk DKK 177.32B 4.86B Mar/2026
Omeros USD 69.65M 26.53M Jun/2025
Pacira USD 514.96M 33.01M Mar/2026
Perrigo USD 2.71B 85M Mar/2026
Pfizer USD 42.82B 76M Mar/2026
Supernus Pharmaceuticals USD 731.58M 87.4M Mar/2026
Teva Pharmaceutical Industries USD 13.71B 236M Mar/2026
Xeris Pharmaceuticals USD 251.68M 11.37M Mar/2026
Xoma USD 110.71M 5.78M Sep/2025
Zoetis USD 6.47B 294M Mar/2026